Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53

• Published in: Cells (Basel, Switzerland) Switzerland), 2022-02, Vol.11 (5), p.794
• Main Authors: Abrams, Stephen L, Duda, Przemysław, Akula, Shaw M, Steelman, Linda S, Follo, Matilde L, Cocco, Lucio, Ratti, Stefano, Martelli, Alberto M, Montalto, Giuseppe, Emma, Maria Rita, Cervello, Melchiorre, Rakus, Dariusz, Gizak, Agnieszka, McCubrey, James A
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Cancer therapies; Carcinoma, Pancreatic Ductal - drug therapy; Carcinoma, Pancreatic Ductal - genetics; Cell culture; Cell growth; Cell Line, Tumor; Chemotherapy; Drugs; Genes; Humans; Leukemia; Metastases; mutant TP53 reactivators; Mutants; Mutation; nutlin-3a; p53 Protein; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - metabolism; Patients; PDAC; Proteins; Quinuclidines - therapeutic use; Signal transduction; targeted therapy; TP53; Tumor suppressor genes; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism; Tumors
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells11050794

The TP53 tumor suppressor is mutated in ~75% of pancreatic cancers. The mutant TP53 protein in pancreatic ductal adenocarcinomas (PDAC) promotes tumor growth and metastasis. Attempts have been made to develop molecules that restore at least some of the properties of wild-type (WT) TP53. APR-246 is one such molecule, and it is referred to as a mutant TP53 reactivator. To understand the potential of APR-246 to sensitize PDAC cells to chemotherapy, we introduced a vector encoding WT-TP53 into two PDAC cell lines, one lacking the expression of TP53 (PANC-28) and one with a gain-of-function (GOF) mutant TP53 (MIA-PaCa-2). APR-246 increased drug sensitivity in the cells containing either a WT or mutant TP53 protein with GOF activity, but not in cells that lacked TP53. The introduction of WT-T53 into PANC-28 cells increased their sensitivity to the TP53 reactivator, chemotherapeutic drugs, and signal transduction inhibitors. The addition of WT-TP53 to PDAC cells with GOF TP53 also increased their sensitivity to the drugs and therapeutics, indicating that APR-246 could function in cells with WT-TP53 and GOF TP53. These results highlight the importance of knowledge of the type of TP53 mutation that is present in cancer patients before the administration of drugs which function through the reactivation of TP53.